Centre. No. of cases | No. treated (%) | No. with confirmed or probable MCD (%) (No. confirmed) | % of those Rx who had MCD | No. identified for treatment by the NBL algorithm (%) | No. identified for treatment by the NICE algorithm (%) |
---|---|---|---|---|---|
Retrospective cohorts | |||||
1. n=230 | 153 (66) | 83 (37) {72} | 54 | 90 (39) | 159* (69) |
2. n=56 | 21 (38) | 13 (23) {8} | 62 | 20 (36) | 31 (55) |
3. n=43 | 26 (60) | 3 (7) {1} | 12 | 18 (42) | 31 (72) |
Pilot cohorts | |||||
4a. n=77 | 48 (62) | 14 (18) {7} | 29 | 35 (46) | 44 (57) |
5. n=42 | 8 (19) | 2 (5) {2} | 25 | 8 (19) | 19 (45) |
6. n=39 | 20 (51) | 9 (23) {7} | 45 | 20 (51) | 23* (59) |
7. n=18 | 9 (50) | 1 (6) {1} | 11 | 9 (50) | 11(61) |
Prospective cohort | |||||
4b. n=120 | 39 (33) | 20 (17) {9} | 51 | 31 (26) | 64* (53) |
Total; 625 | 324 (52) | 145 {107} | 231 (37) | 382 (61) |
*Four children with probable MCD not identified by the NICE algorithm.
MCD, meningococcal disease; NBL, Newcastle-Birmingham-Liverpool; NICE, National Institute for Health and Care Excellence. Rx, treated.